OKYO Pharma’s executive chairman–linked entity has increased its position in the company, with Panetta Partners acquiring 82,018 additional ordinary shares on Nasdaq, bringing the total holding to 10,464,695 shares. The stake build lands just as OKYO completes a randomized, double-masked, placebo-controlled phase 2 trial of urcosimod for neuropathic corneal pain, and follows a 240-patient phase 2 study in dry eye disease that achieved statistical significance on multiple endpoints.
The timing is notable. Insider buying at a clinical inflection point can be read as confidence in near-term data or in the company’s ability to transact. More strategically, it spotlights neuropathic corneal pain as a nascent therapeutic category with high unmet need and no approved therapies. For commercial and medical leaders, the question is whether OKYO can convert a mechanistic and clinical signal into a first-in-class label and a market that payers, cornea specialists, and patients can recognize and navigate.
Urcosimod, formerly OK-101, is a lipid-conjugated chemerin peptide agonist of ChemR23, expressed on ocular immune cells as well as neurons and glial cells. The membrane-anchored design aims to limit tear washout and extend ocular residence, a practical edge for topical dosing where adherence and durability often falter. The anti-inflammatory and analgesic profile supported by preclinical models and dry eye disease phase 2 outcomes sets a plausible bridge to neuropathic pain, but pain trials carry higher placebo risk and hinge on rigorously validated patient-reported endpoints. The specific primary endpoint, magnitude of pain reduction, onset, and durability will determine whether regulators see a path to registration in a condition that remains variably defined and inconsistently coded in routine practice.
Why this matters now is twofold. First, dry eye disease is commercially congested, with payers increasingly demanding clear differentiation on symptoms, signs, and persistence of effect. A pivot to neuropathic corneal pain could offer a cleaner beachhead with strong patient advocacy potential, provided OKYO and its partners help standardize diagnosis, train HCPs on neurosensory phenotyping, and build real-world evidence that maps symptom relief to healthcare utilization and quality-of-life gains. Second, ophthalmology is seeing renewed BD interest in assets that move beyond tear-film mechanics into neuroimmune modulation. If urcosimod’s mechanism translates into consistent pain relief without ocular surface tolerability issues, the asset becomes an attractive bolt-on for established eye-care players seeking pipeline breadth beyond dry eye cycles.
Medical Affairs teams will need to do heavy lifting regardless of the data’s headline. Clear case definitions, reproducible PROs, and accessible diagnostic workflows, including potential use of in vivo confocal microscopy to characterize corneal nerve changes, will be essential to payer conversations and guideline inclusion. Early center-of-excellence networks, pragmatic registries, and longitudinal adherence data could accelerate payer comfort in a category where off-label systemic agents and devices currently fill the void.
For Commercial leaders, pricing power will depend on whether neuropathic corneal pain can be framed as an orphan-like segment with concentrated specialist prescribers or drifts toward the broader, price-sensitive dry eye landscape. A topical analgesic with sustained effect could justify a premium if it demonstrably reduces step therapy churn and improves daily functioning, but only if diagnostic clarity limits leakage into non-responders and ensures predictable outcomes.
All eyes now turn to the phase 2 readout: the definition of the primary endpoint, effect size, dose-response, and safety tolerability. The next strategic signal will be whether OKYO advances alone into pivotal development or secures a partner before phase 3. The sharper question for the sector is whether neuropathic corneal pain can coalesce into a labelable, reimbursable disease state—if it does, it could open a durable new lane in ocular neuroimmune therapeutics and reset expectations for innovation in the dry eye and ocular pain continuum.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
